BioCapital
Filter News
Found 38,220 articles
-
BioSpace Hotbed maps have been a life sciences industry staple for over 30 years. Today the program features eight regional Hotbed Maps and the NextGen Bio Map which highlights some of the industry’s most promising startups.
-
Evergreen Therapeutics, Inc. Announces Agreement with ICON plc to Conduct Phase II Clinical Trial for COVID-19 Drug Candidate
6/18/2021
Evergreen Therapeutics, Inc. today announced a clinical service agreement with ICON plc (“ICON”) to conduct a global, multi-center Phase II clinical trial for Evergreen’s COVID-19 drug therapy candidate EG-009A.
-
Diffusion Pharmaceuticals Reminds Stockholders to Vote Shares In Advance of Annual MeetingAnnual Meeting Scheduled for June 25, 2021, at 1 p.m. EDT
6/18/2021
Diffusion Pharmaceuticals Inc. reminds stockholders to vote on the proposals listed in the Company’s proxy statement in advance of its upcoming annual meeting.
-
The U.S. FDA approved Ayvakit for the treatment of adult patients with advanced sytematic mastocytosis (SM), advanced SM, and mast cell leukemia.
-
Global science and technology innovator Danaher Corporation is adding another company to its ever-growing global operation.
-
Danaher To Acquire Aldevron
6/17/2021
Danaher Corporation (NYSE: DHR) (the "Company") announced today that Danaher has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion.
-
Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases
6/17/2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the expansion of its research program with new drug development projects targeting Prostate Cancer, Neurodegenerative & Mental Health diseases.
-
FDA Approves a Nasal Antihistamine for Nonprescription Use
6/17/2021
The U.S. Food and Drug Administration today approved a nasal antihistamine for nonprescription use through a process called a partial prescription to nonprescription switch.
-
Aura Biosciences Assembles New Bladder Cancer Focused Scientific Advisory Board
6/17/2021
Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, announced the formation of a new, urologic oncology focused Scientific Advisory Board.
-
Novavax to Participate in National Vaccine Advisory Committee Meeting
6/17/2021
Novavax, Inc. today announced that Gregory M. Glenn , M.D., President, Research and Development, will participate in a session during the Department of Health and Human Services' National Vaccine Advisory Committee (NVAC).
-
Novavax to Participate in Fireside Chat at SVB Leerink CybeRx Series: Vaccine Forum
6/17/2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the upcoming 2nd Annual CybeRx Series: Vaccine Forum
-
Both MannKind and United Therapeutics entered into a global and exclusive licensing and collaboration agreement to develop and commercialize Tyvaso DPI.
-
Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma
6/16/2021
Sirnaomics, Inc., today announced that the China National Medical Product Administration (NMPA) has accepted its Investigational New Drug (IND) application for the company's lead candidate, STP705, for the treatment of skin squamous cell carcinoma in situ (isSCC).
-
Inteliquet™ Announces Comprehensive Hematology And Oncology To Join Consortium To Drive Better Patient Matching In Clinical Trials
6/16/2021
Center will contribute to national prioritization of clinical effectiveness through understanding patients as individuals in personalized cancer care.
-
Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members
6/16/2021
Veralox Therapeutics today announced the closing of a $16.6 million Series A financing.
-
MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
6/16/2021
MacroGenics (NASDAQ: MGNX), and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), announced today that the companies have entered into an exclusive collaboration and license agreement involving up to four immuno-oncology molecules.
-
Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers
6/16/2021
Altimmune, Inc. today announced results from a prespecified 6-week interim analysis of its ongoing 12-week, Phase 1, placebo-controlled, single and multiple ascending dose trial of ALT-801.
-
Amalgam Rx™ and Novo Nordisk® Plan Global Expansion
6/16/2021
Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing global expansion of its insulin titration solution with Novo Nordisk.
-
Amalgam Rx™ Receives CE Mark for Basal Insulin Titration
6/16/2021
Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing it has achieved the Conformité Européenne (CE) Mark for its insulin titration application, iSage Rx™ and its white-labeled variants.
-
Important Updates to the 2021 Standards of Medical Care in Diabetes Issued by American Diabetes Association Experts
6/16/2021
The American Diabetes Association® issued important updates to the 2021 Standards of Medical Care in Diabetes, in annotations as the Living Standards of Care.